Sicong Huang1, Vanessa L Kronzer2, Paul F Dellaripa1, Kevin D Deane3, Marcy B Bolster4, Vivek Nagaraja5, Dinesh Khanna5, Tracy J Doyle6, Jeffrey A Sparks1. 1. Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital and Harvard Medical School; Boston, Massachusetts, USA. 2. Division of Rheumatology, Mayo Clinic; Rochester, Minnesota, USA. 3. Division of Rheumatology, University of Colorado; Aurora, Colorado, USA. 4. Division of Rheumatology, Massachusetts General Hospital and Harvard Medical School; Boston, Massachusetts, USA. 5. Division of Rheumatology, University of Michigan; Ann Arbor, Michigan, USA. 6. Division of Pulmonary and Critical Care, Brigham and Women's Hospital and Harvard Medical School; Boston, Massachusetts, USA.
Abstract
PURPOSE OF REVIEW: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is one of the most serious extra-articular RA manifestations. RA-ILD is associated with worse physical function, lower quality of life, and increased mortality. RA-ILD is comprised of heterogeneous subtypes characterized by inflammation and fibrosis. Diagnosis can be difficult since the presentation of RA-ILD is characterized by non-specific symptoms and imaging findings. Management of RA-ILD is also challenging due to difficulty in precisely measuring pulmonary disease activity and response to treatment in patients who may also have articular inflammation. We provide a current overview of RA-ILD focusing on prevalence, risk factors, and treatment. RECENT FINDINGS: Research interest in RA-ILD has increased in recent years. Some studies suggest that RA-ILD prevalence may be increasing; this may be due to underlying biologic drivers or increases in imaging and recognition. Novel RA-ILD risk factors include the MUC5B promotor variant, articular disease activity, autoantibodies, and biomarkers of damaged pulmonary parenchyma. Treatment should focus on controlling RA disease activity, which emerging data suggest may reduce RA-ILD risk. Immunomodulatory and antifibrotic drugs may also treat RA-ILD. SUMMARY: RA-ILD is an underrecognized and serious manifestation of RA, but important progress is being made in identifying risk factors and treatment.
PURPOSE OF REVIEW: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is one of the most serious extra-articular RA manifestations. RA-ILD is associated with worse physical function, lower quality of life, and increased mortality. RA-ILD is comprised of heterogeneous subtypes characterized by inflammation and fibrosis. Diagnosis can be difficult since the presentation of RA-ILD is characterized by non-specific symptoms and imaging findings. Management of RA-ILD is also challenging due to difficulty in precisely measuring pulmonary disease activity and response to treatment in patients who may also have articular inflammation. We provide a current overview of RA-ILD focusing on prevalence, risk factors, and treatment. RECENT FINDINGS: Research interest in RA-ILD has increased in recent years. Some studies suggest that RA-ILD prevalence may be increasing; this may be due to underlying biologic drivers or increases in imaging and recognition. Novel RA-ILD risk factors include the MUC5B promotor variant, articular disease activity, autoantibodies, and biomarkers of damaged pulmonary parenchyma. Treatment should focus on controlling RA disease activity, which emerging data suggest may reduce RA-ILD risk. Immunomodulatory and antifibrotic drugs may also treat RA-ILD. SUMMARY: RA-ILD is an underrecognized and serious manifestation of RA, but important progress is being made in identifying risk factors and treatment.
Authors: Muna Sapkota; Ellen L Burnham; Jane M DeVasure; Jenea M Sweeter; Carlos D Hunter; Michael J Duryee; Lynell W Klassen; Kusum K Kharbanda; Joseph H Sisson; Geoffrey M Thiele; Todd A Wyatt Journal: Alcohol Clin Exp Res Date: 2017-11-04 Impact factor: 3.455
Authors: Jeffrey A Sparks; Xintong He; Jie Huang; Elaine A Fletcher; Alessandra Zaccardelli; H Maura Friedlander; Ritu R Gill; Hiroto Hatabu; Mizuki Nishino; David J Murphy; Christine K Iannaccone; Taysir G Mahmoud; Michelle L Frits; Bing Lu; Ivan O Rosas; Paul F Dellaripa; Michael E Weinblatt; Elizabeth W Karlson; Nancy A Shadick; Tracy J Doyle Journal: Arthritis Rheumatol Date: 2019-08-04 Impact factor: 10.995
Authors: Tracy J Doyle; Namrata Dhillon; Rachna Madan; Fernanda Cabral; Elaine A Fletcher; Diane C Koontz; Rohit Aggarwal; Juan C Osorio; Ivan O Rosas; Chester V Oddis; Paul F Dellaripa Journal: J Rheumatol Date: 2018-04-01 Impact factor: 4.666
Authors: Amir A Razmjou; Jennifer M Wang; Ani Shahbazian; Srinivasa Reddy; Christina Charles-Schoeman Journal: Clin Rheumatol Date: 2022-09-22 Impact factor: 3.650